- Home
- ALLO vs CHW Comparison
ALLO vs CHW Comparison
Compare ALLO & CHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | CHW |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 152 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.4M | 523.0M |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ALLO | CHW |
|---|---|---|
| Price | $2.02 | $8.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $8.35 | N/A |
| AVG Volume (30 Days) | ★ 8.0M | 181.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $6.69 |
| 52 Week High | $4.46 | $8.93 |
Technical Indicators
Market Signals| Indicator | ALLO | CHW |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 63.82 |
| Support Level | $1.85 | $7.90 |
| Resistance Level | $2.71 | N/A |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.33 | 75.24 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.